Guest commentary: FMT, ‘a life-saving therapy,’ needs physician, industry cooperation

In this guest commentary, Jessica Allegretti, MD, MPH, of the Brigham and Women’s Hospital Crohn’s and Colitis Center, discusses the recent FDA hearing on the agency’s policy of enforcement discretion of fecal microbiota transplantation for recurrent Clostridioides difficile infection.Monday in Washington, D.C., I attended a hearing called for by the FDA to discuss the issues surrounding their current policy of enforcement discretion regarding FMT. They had speakers from various subsets – mainly industry collaborators, academic and clinician collaborators, and patientsRead More

Share on facebook
Share on twitter
Share on linkedin